Bartosz Pula

Pabianicka 62 St
Lodz, LD 93513, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Journal: Leukemia & lymphoma

Published: August 10, 2026

Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?

Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?

Journal: Expert review of hematology

Published: August 05, 2026

Risk factors affecting the clinical course of COVID-19 in patients with lymphoid malignancies in the Omicron subvariants era - a real-world analysis by the Polish Adult Lukemia Study Group.

Risk factors affecting the clinical course of COVID-19 in patients with lymphoid malignancies in the Omicron subvariants era - a real-world analysis by the Polish Adult Lukemia Study Group.

Journal: Annals of agricultural and environmental medicine : AAEM

Published: June 30, 2026

Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs.

Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs.

Journal: Expert review of hematology

Published: June 02, 2026

Advancing Immunotherapy in Chronic Lymphocytic Leukemia.

Advancing Immunotherapy in Chronic Lymphocytic Leukemia.

Journal: International journal of molecular sciences

Published: March 02, 2026

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 21, 2025

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

Journal: Journal of clinical medicine

Published: October 27, 2025

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Journal: Contemporary oncology (Poznan, Poland)

Published: October 16, 2025

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.

Journal: British journal of haematology

Published: October 09, 2025

Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?

Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?

Journal: Expert review of hematology

Published: August 08, 2025

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.

Journal: Leukemia & lymphoma

Published: August 01, 2025

Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?

Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?

Journal: Expert opinion on investigational drugs

Published: May 02, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026